Total Payments
$196,600
2024 Payments
$25,486
Companies
5
Transactions
126
Medicare Patients
148
Medicare Billing
$19,867
Payment Breakdown by Category
Consulting$182,565 (92.9%)
Research$14,014 (7.1%)
Food & Beverage$20.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $182,565 | 112 | 92.9% |
| Unspecified | $14,014 | 13 | 7.1% |
| Food and Beverage | $20.95 | 1 | 0.0% |
Payments by Type
General
$182,586
113 transactions
Research
$14,014
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $154,465 | 104 | $0 (2024) |
| Gilead Sciences, Inc. | $15,050 | 6 | $0 (2024) |
| Genentech, Inc. | $14,014 | 13 | $0 (2019) |
| PFIZER INC. | $13,050 | 2 | $0 (2022) |
| ABBVIE INC. | $20.95 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,486 | 17 | Merck Sharp & Dohme LLC ($21,965) |
| 2023 | $33,750 | 27 | Merck Sharp & Dohme LLC ($23,250) |
| 2022 | $37,300 | 26 | Merck Sharp & Dohme LLC ($34,000) |
| 2021 | $34,425 | 18 | Merck Sharp & Dohme LLC ($23,625) |
| 2020 | $22,125 | 12 | Merck Sharp & Dohme Corporation ($22,125) |
| 2019 | $17,660 | 8 | Merck Sharp & Dohme Corporation ($11,000) |
| 2018 | $17,999 | 13 | Merck Sharp & Dohme Corporation ($16,750) |
| 2017 | $7,855 | 5 | Genentech, Inc. ($6,105) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 2 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $437.50 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $437.50 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $437.50 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: ONCOLOGY | ||||||
| 09/01/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 09/01/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 08/21/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 04/24/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 01/25/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 01/25/2023 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,187.50 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,187.50 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2022 | Merck Sharp & Dohme LLC | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2022 | Merck Sharp & Dohme LLC | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC | Genentech, Inc. | $8,880 | 4 |
| 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | Genentech, Inc. | $1,745 | 3 |
| 1L NSCLC DX ALL COMER SQUAMOUS | Genentech, Inc. | $1,694 | 3 |
| 1L NSCLC DX ALL COMER NON SQUAMOUS | Genentech, Inc. | $1,694 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 53 | 98 | $25,443 | $6,433 |
| 2022 | 3 | 57 | 103 | $27,245 | $6,470 |
| 2021 | 1 | 12 | 52 | $12,168 | $2,992 |
| 2020 | 2 | 26 | 70 | $16,369 | $3,972 |
Total Patients
148
Total Services
323
Medicare Billing
$19,867
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 65 | $15,210 | $3,869 | 25.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 21 | 21 | $4,893 | $1,337 | 27.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $5,340 | $1,227 | 23.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 66 | $15,444 | $3,692 | 23.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $6,675 | $1,548 | 23.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 22 | 22 | $5,126 | $1,230 | 24.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 52 | $12,168 | $2,992 | 24.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 15 | 59 | $13,806 | $3,315 | 24.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 11 | 11 | $2,563 | $656.15 | 25.6% |
About Dr. David Johnson, MD
Dr. David Johnson, MD is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013009422.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Johnson, MD has received a total of $196,600 in payments from pharmaceutical and medical device companies, with $25,486 received in 2024. These payments were reported across 126 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($182,565).
As a Medicare-enrolled provider, Johnson has provided services to 148 Medicare beneficiaries, totaling 323 services with total Medicare billing of $19,867. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Dallas, TX
- Active Since 09/30/2006
- Last Updated 01/08/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1013009422
Products in Payments
- KEYTRUDA (Biological) $53,000
- LENVIMA (Drug) $28,375
- LYNPARZA (Biological) $19,365
- TECENTRIQ (Biological) $8,880
- Tarceva (Drug) $3,440
- MK-7339 (Drug) $2,000
- Avastin (Biological) $1,694
- IMBRUVICA (Drug) $20.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Moshe Levy, Md, MD
Medical Oncology — Payments: $5.0M
Medical Oncology $5.0M
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Joyce O'shaughnessy, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD
Medical Oncology — Payments: $1.3M
Medical Oncology $1.3M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Ashwani Agarwal, M.d, M.D
Medical Oncology — Payments: $304,262
Medical Oncology $304,262